Technological transfer & Partnership with industry
Jérôme Castandet
Business Developer
Since its foundation, the IPBS has been active in creating and maintaining partnerships with industry. Any important new results obtained by IPBS scientists are carefully evaluated for patentability, potential therapeutic applications, and industrial or commercial exploitation.
The Business Developer’s mission is to promote the scientific expertise of the IPBS and CBI research teams and technological platforms. He is in charge of developing public/private partnerships by scientific collaborations or outsourcing services.
The first public-private high-throughput screening centre between the CNRS and Pierre Fabre S.A. was active at IPBS from 1999 to 2003. Since 1999, nine biotechnology companies started or were incubated at IPBS. At present, 12 patent families have been filed, nearly 95 agreements per year are concluded, and more than 50 applications for patents or their extensions involve IPBS researchers as inventors or co-inventors.
In 2020, the IPBS welcomed the small biotech G.CLIPS, which proposes solutions for the research of therapeutic agents targeting membrane proteins.
0
small biotech companies
have been started or incubated at IPBS.
More than
0
collaborative or subcontracting
partnerships were signed with industrial partners*
*Including Adisseo, Agri-Intranet, Agronutrition, Antabio, Asconit, Chromalys, EDF, Evotec, Genclis, GSK, GTP Technology, Innopsys, Invivogen, ITHPPAlcen, Janssen Cilag, Lacaze Energies, Magellium, Picometrics, Pierre Fabre, Roche, Sanofi Pasteur, Sanofi-Aventis, Société d’ingénierie et de réalisations électriques et d’automatismes, TTT, Total, UCB Pharma, UroSphere, Vectalys, Virbac, ZoBio…
The IPBS is working in close collaboration with the CNRS Technology Transfer Office and the Société d’Accélération du Transfert de Technologies (SATT), Toulouse Tech Transfer (TTT), which monitors and supports the patenting processes to ensure sustainability of our patenting activity. TTT is involved in surveying our activities and identifying which products could be developed and for which market, and supporting technical operations to design relevant proofs of concept and/or prototypes to trigger industrial interest for our products and technologies. TTT also supports the creation of start-ups and several IPBS scientists have expressed their interest in developing start-ups in the future. Dedicated actions will be taken to ensure success.
In 2021, the IPBS steering committee decided to set up a Committee in charge of valorisation and relations with industry and the clinic (CoVALO) whose main mission is to detect, promote, support, protect and transfer inventions arising from scientific findings. The committee includes the IPBS office for industrial partnership, IPBS scientists, representatives of TTT, representatives of the Eurobiomed cluster and representatives of the private sector, and works to identify projects with a strong potential for valorisation, which could be supported in the form of seed funding. The CoVALO also identifies funding opportunities for valorisation (pre-maturation and maturation) available to IPBS researchers as well as the different structures that can provide support to valorisation and transfer actions.
Strengthening exchanges with Industry through the CIFRE initiative
The CIFRE (Convention Industrielle de Formation par la Recherche) programme is designed to encourage the development of public-private partnership research by co-financing the training of doctoral students recruited by a company. The research mission entrusted to the students is part of the R&D strategy of the industrial actor; it is shared with an academic laboratory, under a collaboration contract, and will be used as support for the preparation of the doctoral student’s thesis, in compliance with the order of August 7, 2006 relating to doctoral training. Each year, the IPBS accompanies the training of several doctoral students within the CIFRE framework.